AstraZeneca: TAGRISSO Granted Priority Review in the US for Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer
June 11, 2024
June 11, 2024
WILMINGTON, Delaware, June 11 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Decision based on LAURA Phase III trial results which extended median progression-free survival by more than three years
TAGRISSO also granted Breakthrough Therapy Designation in US in this setting
* * *
AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO(R) (osimertinib) has been accepted and . . .
* * *
Decision based on LAURA Phase III trial results which extended median progression-free survival by more than three years
TAGRISSO also granted Breakthrough Therapy Designation in US in this setting
* * *
AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO(R) (osimertinib) has been accepted and . . .